About Brian Halak
Brian Halak, PhD, sits on SonoThera's board and is a senior advisor at Medical Excellence Capital, which he joined as a managing partner in 2021. He is still a partner managing Domain Associates' existing funds, and from 2015 to early 2019 he was president and CEO of WindMIL Therapeutics.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Brian Halak in the role, so the role may have started earlier or lasted longer.
MC
Medical Excellence Capital Current
Senior Advisor (2026 – Present)
Managing Partner (2021 – 2026)
2021 – Present
DA
Domain Associates Current
Partner
2006 – Present
EV
Elm Street Ventures Current
Advisor
SonoThera, Inc.
Director
2022 – 2026 · South San Francisco, CA
SonoThera develops nonviral genetic medicines that use ultrasound and imaging microbubbles to deliver DNA and RNA into chosen organs, starting with Duchenne muscular dystrophy.
AI
Alimera Sciences Inc.
Director
2010 – 2023 · Public company (ALIM)
VI
Vyome Holdings, Inc
10% owner
2016 – 2019 · Public company (HIND)
AI
Adynxx, Inc.
10% owner
2019 · Public company (ADYX)
WT
WindMIL Therapeutics
President and CEO
2015 – 2019
DI
Dicerna Pharmaceuticals Inc
Director and 10% owner
2014 – 2018 · Public company (DRNA)
BI
Bionano Genomics, Inc.
10% owner
2018 · Public company (BNGO)
OI
Ocera Therapeutics, Inc.
10% owner
2013 – 2017 · Public company (OCRX)
TI
Tobira Therapeutics, Inc.
10% owner
2013 – 2016 · Public company (TBRA)
EI
Evoke Pharma Inc
10% owner
2013 – 2016 · Public company (EVOK)
SI
Syndax Pharmaceuticals Inc
10% owner
2016 · Public company (SNDX)
GC
Glaukos Corp.
10% owner
2015 · Public company (GKOS)
AI
aTYR PHARMA INC
10% owner
2015 · Public company (ATYR)
EI
Esperion Therapeutics, Inc.
10% owner
2013 – 2015 · Public company (ESPR)
EI
Evofem Biosciences, Inc.
10% owner
2014 · Public company (EVFM)
DI
Durata Therapeutics, Inc.
10% owner
2012 – 2014 · Public company (DRTX)
AI
Atara Biotherapeutics, Inc.
10% owner
2014 · Public company (ATRA)
VI
Veracyte, Inc.
10% owner
2013 – 2014 · Public company (VCYT)
OI
Otonomy, Inc.
10% owner
2014 · Public company (OTIC)
MI
Marinus Pharmaceuticals, Inc.
10% owner
2014 · Public company (MRNS)
AI
Aldeyra Therapeutics, Inc.
10% owner
2014 · Public company (ALDX)
CI
Cadence Pharmaceuticals Inc.
10% owner
2006 – 2014 · Public company (CADX)
AI
Achaogen, Inc.
10% owner
2014 · Public company (AKAO)
TI
Tandem Diabetes Care Inc.
10% owner
2013 · Public company (TNDM)
CI
Clovis Oncology, Inc.
10% owner
2011 – 2013 · Public company (CLVS)
AI
Achillion Pharmaceuticals Inc.
10% owner
2010 – 2013 · Public company (ACHN)
CI
Celator Pharmaceuticals Inc
10% owner
2013 · Public company
OI
Orexigen Therapeutics, Inc.
10% owner
2007 – 2011 · Public company (OREXQ)
ZI
Zogenix, Inc.
10% owner
2010 – 2011 · Public company (ZGNX)
VI
Vanda Pharmaceuticals Inc.
Director
2006 – 2010 · Public company (VNDA)
VC
Volcano Corp
10% owner
2007 – 2008 · Public company (VOLC)
PI
Paratek Pharmaceuticals, Inc.
10% owner
2006 · Public company (PRTK)
NI
Northstar Neuroscience, Inc.
Director
2006 · Public company (NSTR)
NT
Nobias Therapeutics
Co-founder
EP
Esprit Pharma
Director
DT
Dicerna Therapeutics
Director
AV
Advanced Technology Ventures
Associate
TG
The Wilkerson Group
Consultant
Education
- BSE, Bioengineering, University of Pennsylvania
- PhD, Immunology, Thomas Jefferson University
Key Colleagues at Startups
The people Brian Halak works with at each company, as listed on that company's latest Form D.
SonoThera, Inc. · Form D, Jun 30, 2026
SF
Steven Feinstein
Co-founder & Chief Scientific Officer
KG
Kenneth Greenberg
Co-founder, President & CEO, director
MD
Michael Davidson
Co-founder & Executive Chairman
RJ
Rajul Jain
Director
SG
Steven Gillis
Director
Rakhshita Dhar
Director
CZ
Carolyne Zimmermann
Chief Business Officer